More serious but rare adverse effects include pancreatitis, gallbladder disease, and potential thyroid concerns (based on animal studies, though human risk remains unclear)
GLP-1 and Beyond: What Everyone Needs to Know Format: Instant access | Digital | Self-Paced | Certificate of Attendance | Lifetime Access GLP-1 medications, such as Ozempic, Wegovy, and Mounjaro are transforming conversations about weight, health, and treatment options
The Ozempic Savings Card program is not available to individuals without insurance coverage for Ozempic and those with government-sponsored insurance
But when it reaches the market, here's what to expect based on the current GLP-1 insurance landscape: If Approved for Type 2 Diabetes Most commercial insurance plans will cover it, especially if it demonstrates A1C reduction comparable to or exceeding tirzepatide Prior authorization will likely be required Step therapy (try metformin first, then other agents) is standard Copays with manufacturer savings: potentially $25$50/month If Approved for Obesity/Weight Management Coverage remains highly variable, and many plans still exclude weight management medications Medicare Part D: Congress has been debating coverage of anti-obesity medications, but it remains excluded as of early 2026 Self-insured employers increasingly adding GLP-1 coverage, but it's employer-specific Expect significant prior authorization requirements (BMI thresholds, failed diet attempts) The practical reality: even when retatrutide is approved, many people will face the same insurance barriers that currently exist for Wegovy and Zepbound
Compounding has been a part of the pharmaceutical world for centuries
